Literature DB >> 33552173

Recommended Academic Reading.

.   

Abstract

Year:  2021        PMID: 33552173      PMCID: PMC7837519     

Source DB:  PubMed          Journal:  J Can Acad Child Adolesc Psychiatry        ISSN: 1719-8429


× No keyword cloud information.
  5 in total

1.  Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder.

Authors:  Laurence L Greenhill; James M Swanson; Lily Hechtman; James Waxmonsky; L Eugene Arnold; Brooke S G Molina; Stephen P Hinshaw; Peter S Jensen; Howard B Abikoff; Timothy Wigal; Annamarie Stehli; Andrea Howard; Michael Hermanussen; Tomasz Hanć
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-08-15       Impact factor: 8.829

2.  Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.

Authors:  C Lindsay DeVane; Jane M Charles; Ruth K Abramson; John E Williams; Laura A Carpenter; Sarah Raven; Frampton Gwynette; Craig A Stuck; Mark E Geesey; Catherine Bradley; Jennifer L Donovan; Alicia G Hall; Shelley T Sherk; Nancy R Powers; Eve Spratt; Anne Kinsman; Markus J Kruesi; John E Bragg
Journal:  Pharmacotherapy       Date:  2019-05-29       Impact factor: 4.705

3.  Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study.

Authors:  L Ramerman; G de Kuijper; T Scheers; M Vink; P Vrijmoeth; P J Hoekstra
Journal:  J Intellect Disabil Res       Date:  2019-01-04

4.  A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder.

Authors:  Suresh Durgam; Changzheng Chen; Raffaele Migliore; Chandran Prakash; John Edwards; Robert L Findling
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

5.  A Randomized, Double-Blind, Placebo-Controlled Trial of Vilazodone in Children and Adolescents with Major Depressive Disorder with Twenty-Six-Week Open-Label Follow-Up.

Authors:  Robert L Findling; Emily McCusker; Jeffrey R Strawn
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-05-27       Impact factor: 2.576

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.